8-K: Beauty Health Appoints Pedro Malha as New CEO

The Beauty Health Company announces Pedro Malha as its new President and CEO, effective October 1, 2025, succeeding Marla Beck.

Summary

• Pedro Malha has been appointed President and Chief Executive Officer of The Beauty Health Company, effective October 1, 2025.
• Mr. Malha will also join the company's Board of Directors, effective October 1, 2025.
• Marla Beck will step down from her roles as Chief Executive Officer, President, and director, effective September 30, 2025, and will transition to an advisory role until no later than December 31, 2025.
• Mr. Malha's compensation package includes an annual base salary of $800,000, a one-time cash bonus of $450,000, and an annual cash performance bonus targeted at 125% of his base salary.
• He will receive an initial long-term incentive equity grant award of $2,556,000 (75% Restricted Stock Units, 25% Performance Share Units) and a fiscal year 2025 equity grant award of $2,000,000 (75% Restricted Stock Units, 25% Performance Share Units).
• The 2026 long-term incentive award is expected to have a target grant-date value of approximately $4,000,000.
• Mr. Malha brings over two decades of global experience in the healthcare and medical device industries, having held senior leadership positions at Abbott Laboratories, Zimmer Biomet Holdings, and Johnson & Johnson.

Sentiment

Score: 8

Explanation: The appointment of Pedro Malha, an executive with over two decades of experience in global healthcare and medical device sectors, is a strong positive. The smooth transition with the outgoing CEO remaining in an advisory role, coupled with management's optimistic statements about future growth and innovation, indicates a favorable outlook for the company's strategic direction.

Positives

• The appointment of Pedro Malha, an executive with over two decades of experience in global healthcare and medical device sectors, is expected to bring strong leadership and operational expertise.
• Mr. Malha's background includes a proven track record of delivering growth and operational excellence at leading multinational companies.
• The outgoing CEO, Marla Beck, will remain in an advisory role, ensuring a smooth transition and continuity of knowledge.
• The Chairman of the Board stated that the company is 'well positioned for sustainable and profitable growth' following Ms. Beck's tenure.

Risks

• Forward-looking statements contained in the filing are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict.
• Actual outcomes and results may differ materially from what is expressed in forward-looking statements.
• Executive compensation, including Mr. Malha's, may be subject to excise tax under Section 4999 of the Internal Revenue Code, potentially leading to reductions in total payments.
• Equity awards are subject to clawback or recoupment policies if the executive commits an act constituting 'Cause' that results in material harm to the company.

Future Outlook

The Chairman of the Board stated that the company is 'well positioned for sustainable and profitable growth.' The outgoing CEO noted a 'robust pipeline of innovation and bold brand initiatives currently underway.' The new CEO expressed a commitment to 'shape the future of skin health through continued science-backed innovation and operational excellence, while accelerating profitable growth and creating lasting value for stakeholders around the world.' The 2026 long-term incentive award for the new CEO is expected to have a target grant-date value of approximately $4,000,000.

Management Comments

• Brent Saunders, Chairman of the Board: 'Pedro is an accomplished leader with broad industry experience at leading multinational companies in the healthcare and medical device sectors. His ability to navigate complex global markets and build collaborative, high-performing teams makes him the right person to lead BeautyHealth into its next chapter. We are also grateful for Marlas strong leadership during a pivotal period of transformation, which has left BeautyHealth well positioned for sustainable and profitable growth.'
• Marla Beck: 'I am incredibly proud of what we have accomplished together to strengthen BeautyHealths foundation and future. With the right team and strategy in place, I believe now is the right time to welcome a new CEO to lead the Company into its next phase of growth. BeautyHealth has a robust pipeline of innovation and bold brand initiatives currently underway, and I look forward to watching the Company continue to thrive under Pedros leadership.'
• Pedro Malha: 'I am honored to join BeautyHealth and lead this exceptional Company into the future. Hydrafacial is a category-defining brand with unmatched potential at the intersection of beauty and health. I look forward to working alongside the Board, the leadership team, and our global community of providers to shape the future of skin health through continued science-backed innovation and operational excellence, while accelerating profitable growth and creating lasting value for stakeholders around the world.'

Industry Context

Mr. Malha's extensive background in the global healthcare and medical device industries aligns strategically with The Beauty Health Company's positioning as a 'medtech meets beauty company' and its focus on 'performance skin health' through brands like Hydrafacial. This leadership change suggests a continued emphasis on leveraging technological and medical expertise to drive innovation and growth within the evolving beauty and wellness market, which increasingly values science-backed solutions.

Comparison to Industry Standards

• Pedro Malha's previous roles as Worldwide Division President and Corporate Officer at Abbott Laboratories, and senior leadership positions at Zimmer Biomet Holdings and Johnson & Johnson, demonstrate a career trajectory consistent with high-caliber executive appointments in the global healthcare and medical device sectors.
• The compensation structure, including a substantial base salary, one-time cash bonus, and significant equity grants (RSUs and PSUs), is competitive and aligns with industry standards for attracting and retaining top-tier CEO talent in publicly traded companies within the medtech and beauty sectors.
• The inclusion of performance-based equity (PSUs) tied to Relative Total Shareholder Return (TSR) against a blended peer group (including BeautyHealth's Compensation Peer Group and the Dow Jones US Select Medical Equipment Index) reflects a common industry practice to align executive incentives with shareholder value creation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact from new leadership with extensive industry experience, aiming for 'sustainable and profitable growth' and 'creating lasting value for stakeholders.' The transition is framed as a strategic move for future growth.
• Employees: A change in CEO can lead to shifts in company culture or strategy. The filing emphasizes continuity and future growth, which could be positive for employee morale, but specific impacts on roles are not detailed.
• Customers/Providers: The new CEO's focus on 'science-backed innovation and operational excellence' could lead to enhanced products/services and improved customer experience for Hydrafacial users and providers, reinforcing the brand's position in the market.

Next Steps

• Pedro Malha's official start as President and CEO on October 1, 2025.
• Marla Beck to serve in an advisory role until no later than December 31, 2025.
• The company intends to enter into a separation agreement with Ms. Beck as soon as practicable and will file it as an exhibit to an amendment to this Current Report.
• The Board or Compensation Committee will set specific performance goals for Mr. Malha's annual cash performance bonus for fiscal year 2025 and subsequent years.
• The Board or Compensation Committee will determine future long-term incentive awards for Mr. Malha, with the 2026 award expected to target approximately $4,000,000.

Key Dates

Recommendation

The appointment of Pedro Malha, an experienced leader from the healthcare and medical device sectors, is a positive development that could bring fresh perspectives and operational expertise. However, CEO transitions inherently carry a degree of uncertainty as the new leader implements their vision. While the filing highlights a smooth transition and positive outlook, it does not provide immediate financial results or guidance that would warrant a 'buy' recommendation. Investors should 'hold' to observe the execution of the new leadership's strategy and its impact on financial performance before making further investment decisions.

Keywords

Beauty Health Company, Hydrafacial, CEO appointment, executive change, Pedro Malha, Marla Beck, corporate governance, leadership transition, medical device, skin health, Abbott Laboratories, Zimmer Biomet, executive compensation, restricted stock units, performance share units